This article was originally published in The Gray Sheet
Letter of intent is signed under which urinary incontinence treatment firm Uroplasty will purchase Empi's Clinical EMG System for $400,000. The product is a biofeedback device used to treat UI. Closing of the deal is subject to certain conditions, including the negotiation and execution of a definitive agreement and Uroplasty's due diligence review of "certain software" related to the system, according to Minneapolis-based Uroplasty, which is developing the Macroplastique injectable treatment for female stress UI
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.